Maternal obesity and its impact on pregnancy

Shambhavi Soni1, Himanshy Rai1, Mohita Pandey2

  • 1Department of Obstetrics and Gynecology, Government Medical College, Datia, Madhya Pradesh, India.

Bioinformation
|March 30, 2026
PubMed

Maternal obesity is associated with a significantly increased risk of complications across all stages of pregnancy. Implementing targeted interventions can help mitigate obesity-related risks and improve overall pregnancy outcomes. Hence, a cross-sectional study was conducted from September 2022 to September 2023 at a tertiary care hospital of Central India to assess the prevalence of obesity among pregnant women and to evaluate its impact on pregnancy complications, mode of delivery and fetal outcomes. Data of 80 pregnant women (BMI >30 kg/m2) with obesity, on demographics, medical history, physical activity and dietary practices were collected. Relevant investigations, including glucose tolerance tests, ultrasound scans, blood tests, were performed and Maternal and fetal outcomes were analyzed. Obesity was linked to higher rates of gestational diabetes, hypertensive disorders, and anemia. Intrapartum challenges, including prolonged and preterm labor, were more common, with higher cesarean delivery rates. Postpartum morbidity, particularly hemorrhage, wound infections, and episiotomy dehiscence, was notably higher. These findings highlight the need for integrated strategies to mitigate the adverse effects of obesity on pregnancy.

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.4K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
339
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
282
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
381